Anglia Ruskin Research Online (ARRO)
Browse
DOCUMENT
Zhukovsky_et_al_2021.pdf (1.4 MB)
.DOCX
Zhukovsky_et_al_2021.docx (2.27 MB)
1/0
2 files

Prefrontal cortex activation and stopping performance underlie the beneficial effects of atomoxetine on response inhibition in healthy and cocaine use disorder volunteers

journal contribution
posted on 2023-08-30, 19:02 authored by Peter Zhukovsky, Sharon Morein-Zamir, Hisham Ziauddeen, Emilio Fernandez-Egea, Chun Meng, Ralf Regenthal, Barbara J. Sahakian, Edward T. Bullmore, Trevor W. Robbins, Jeffrey W. Dalley, Karen D. Ersche
Background- Impaired response inhibition in individuals with cocaine use disorder (CUD) is hypothesised to depend on deficient noradrenergic signalling in cortico-striatal networks. Remediation of noradrenergic neurotransmission with selective norepinephrine reuptake inhibitors such as atomoxetine may therefore have clinical utility to improve response inhibitory control in CUD. Methods- We carried out a randomised, double-blind, placebo-controlled, crossover study with 26 CUD participants and 28 control volunteers investigating the neural substrates of stop-signal inhibitory control. The effects of a single dose of atomoxetine (40 mg) were compared with placebo on stop-signal reaction time performance and functional network connectivity using dynamic causal modelling. Results- We found that atomoxetine speeded Go response times in both control and CUD participants. Improvements in stopping efficiency on atomoxetine were conditional on baseline (placebo) stopping performance and were directly associated with increased inferior frontal gyrus activation. Further, stopping performance, task-based brain activation and effective connectivity were similar in the two groups. Dynamic causal modelling of effective connectivity of multiple prefrontal and basal ganglia regions replicated and extended previous models of network function underlying inhibitory control to CUD and control volunteers and showed subtle effects of atomoxetine on prefrontal-basal ganglia interactions. Conclusions- These findings demonstrate that atomoxetine improves response inhibition in a baseline-dependent manner in control and in CUD participants. Our results emphasize inferior frontal cortex function as a future treatment target due to its key role in improving response inhibition in CUD.

History

Refereed

  • Yes

Volume

0

Issue number

0

Page range

0

Publication title

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging

ISSN

2451-9022

Publisher

Elsevier

File version

  • Accepted version

Language

  • eng

Legacy posted date

2021-09-10

Legacy creation date

2021-09-10

Legacy Faculty/School/Department

Faculty of Science & Engineering

Usage metrics

    ARU Outputs

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC